Folinic Acid

• PRODIGE 33 - BALLAD - Phase III study to evaluate the benefit of adjuvant chemotherapy in small bowel adenocarcinoma. Ended
  2024-515299-11-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• Randomized and multicentre Phase II study of FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) alone or in combination with hepatic chemoe… Ended
  2024-517782-16-00 Phase II 1 country Grupo Espanol Multidisciplinar En Cancer Digestivo
• The role of sonoporation-enhanced treatment in patients with inoperable pancreatic cancer Ended
  2024-512176-35-00 Phase II 1 country Helse Bergen HF
• ELVN-002 combined with trastuzumab +/- chemotherapy in HER2 + Solid Tumors Ended
  2023-509716-29-00 Phase I/II 5 countries Enliven Therapeutics Inc.
• ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRE… Ended
  2023-508615-24-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Phase 2 Futibatinib in Combination with PD-1 Antibody-based Standard of Care in Solid Tumors Ended
  2023-507516-12-00 Phase II 3 countries Taiho Oncology Inc.
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended
  2023-503265-27-00 Phase III 14 countries Glaxosmithkline Research & Development Limited
• METIMMOX-2: Oxaliplatin Chemotherapy and Immunotherapy to Patients with the Common pMMR/MSS Type of Large Bowel Cancer Spread to Other Organ… Ended
  2022-500027-76-00 Phase II 1 country Akershus University Hospital
• This study is to understand how well an investigational drug (called Napabucasin) works when given in combination with a chemotherapy treatm… Ended
  2024-518204-50-00 Phase III 2 countries 1globe Health Institute LLC
• Lutetium (177Lu) Edotreotide versus Best Standard of Care in Well-differentiated Aggressive Grade 2 and Grade 3 Gastroenteropancreatic Neuro… Ended
  2024-510812-64-00 Phase III 5 countries ITM Solucin GmbH
• An open-label phase 1b/2 study assessing the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic… Ended
  2024-514905-79-00 Phase I/II 3 countries Alligator Bioscience AB
• Induction chemotherapy for locally advanced rectal cancer. Ended
  2023-509758-74-00 Phase II 1 country Catharina Ziekenhuis Stichting
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou… Ended
  2023-509405-77-00 Phase III 13 countries Pfizer Inc.
• This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended
  2023-507338-26-00 Phase III 8 countries Astrazeneca AB
• Hepatic arterial infusion PUMP chemotherapy combined with systemIc chemoTherapy for potentially resectable colorectal liver metastases. - Th… Ended
  2024-515525-28-00 Phase II/III 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
• A Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherap… Ended
  2022-501531-16-00 Phase III 10 countries Merck Sharp & Dohme LLC
• Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended
  2024-512165-13-00 Phase II 1 country Unicancer
• Clinical trial to compare the efficacy of two treatment sequencing schemes with chemotherapy (the regime called FOLFOX and FOLFIRI) in combi… Ended
  2024-510967-41-00 Phase III 2 countries Asociacion Grupo Tratamiento De Tumores Digestivos
• A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination with Chemotherapy and/or Immunotherapy in Subjects with Metastat… Ended
  2024-511649-21-00 Phase II 2 countries Astellas Pharma Global Development Inc.
• Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended
  2024-510645-34-00 Phase II 1 country Unicancer
• IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting Ended
  2024-517489-41-00 Phase III 2 countries Unicancer
• PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient… Ended
  2024-518741-21-00 Phase II 2 countries Fondation Franc.Cancerologie Digestive
• IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac… Halted
  2024-517254-99-00 Phase II 1 country Hospices Civils De Lyon

Showing 49–72 of 86 trials